Publications

Authors:

Santangelo, Alessandra; Rossato, Marzia; Lombardi, Giuseppe; Benfatto, Salvatore; Lavezzari, Denise; Luca De Salvo, Gian; Indraccolo, Stefano; Cristina Dechecchi, Maria; Prandini, Paola; Gambari, Roberto; Scapoli, Chiara; DI GENNARO, Gianfranco; Caccese, Mario; Eoli, Marica; Rudà, Roberta; Ariela Brandes, Alba; Ibrahim, Toni; Rizzato, Simona; Lolli, Ivan; Lippi, Giuseppe; Delledonne, Massimo; Zagonel, Vittorina; Cabrini, Giulio

Title:

A molecular signature associated with prolonged survival in glioblastoma patients treated with Regorafenib

Year:

2021

Type of item:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Language:

Inglese

Format:

A Stampa

Referee:

Sì

Name of journal:

NEURO-ONCOLOGY

ISSN of journal:

1522-8517

N° Volume:

23

Number or Folder:

2

Page numbers:

264-276

Keyword:

CDKN1A; HIF1A; glioblastoma; miR-93-5p; regorafenib

Short description of contents:

Background: Patients with glioblastoma (GBM) have a dramatically poor prognosis. The recent REGOMA trial suggested an overall survival benefit of regorafenib in recurrent GBM patients. Considering the extreme genetic heterogeneity of GBMs, we aimed to identify molecular biomarkers predictive of differential response to the drug. Methods: Total RNA was extracted from tumor samples of patients enrolled in the REGOMA trial. Genome-wide transcriptome and miRNA profiles were associated with patients' Overall Survival (OS) and Progression Free Survival (PFS). Results: At first step, a set of 11 gene transcripts (HIF1A, CTSK, SLC2A1, KLHL12, CDKN1A, CA12, WDR1, CD53, CBR4, NIFK-AS1, RAB30-DT) and 10 miRNAs (miR-93-5p, miR-203a-3p, miR-17-5p, let-7c-3p, miR-101-3p, miR-3607-3p, miR-6516-3p, miR-301a-3p, miR-23b-3p, miR-222-3p) was filtered by comparing survival between regorafenib and lomustine arms. As second step, a minisignature of two gene transcripts (HIF1A, CDKN1A) and three miRNAs (miR-3607-3p, miR-301a-3p, miR-93-5p) identified a subgroup of patients showing prolonged survival after regorafenib administration (median OS range 10.6 - 20.8 months). Conclusions: The study provides evidence that a signature based on the expression of five biomarkers could help identifying a subgroup of GBM patients exhibiting a striking survival advantage when treated with regorafenib. Despite the presented results must be confirmed in larger replication cohorts, the study highlights potential biomarker options to help guiding the clinical decision among regorafenib and other treatments in patients with relapsing GBM.

Note:

Alessandra Santangelo, Marzia Rossato, and Giuseppe Lombardi contributed equally to this work. Giulio Cabrini, Vittorina Zagonel, and Giuseppe Lippi share senior authorship.

Web page:

https://academic.oup.com/neuro-oncology/article/doi/10.1093/neuonc/noaa156/5871069

Product ID:

115455

Handle IRIS:

11562/1021574

Last Modified:

May 21, 2023

Bibliographic citation:

Santangelo, Alessandra; Rossato, Marzia; Lombardi, Giuseppe; Benfatto, Salvatore; Lavezzari, Denise; Luca De Salvo, Gian; Indraccolo, Stefano; Cristina Dechecchi, Maria; Prandini, Paola; Gambari, Roberto; Scapoli, Chiara; DI GENNARO, Gianfranco; Caccese, Mario; Eoli, Marica; Rudà, Roberta; Ariela Brandes, Alba; Ibrahim, Toni; Rizzato, Simona; Lolli, Ivan; Lippi, Giuseppe; Delledonne, Massimo; Zagonel, Vittorina; Cabrini, Giulio, A molecular signature associated with prolonged survival in glioblastoma patients treated with Regorafenib «NEURO-ONCOLOGY» , vol. 23 , n. 2 , 2021 , pp. 264-276

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo